Fibrosure test. FibroMeter utilizes an expert system to detect anomalous profiles and maximize diagnostic reliability. Specifically, the FibroSure score provides a quantitative assessment of liver damage In nonalcoholic fatty liver disease (NAFLD), advanced fibrosis has been identified as an important prognostic factor with increased liver-related mortality and treatment need. It is associated with obesity, diabetes, and dyslipidemia Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Mar 1, 2019 · Staging of liver fibrosis is increasingly done using noninvasive methods, in some cases obviating the need for liver biopsy. 5mL serum from gel-barrier tube Acceptable Specimen: 3. G&H What role does fibrosis monitoring play in the care of patients with chronic liver disease? NA Standard-of-care practice, specifically for hepatitis C, is to utilize the stage of disease to guide treatment decision-making. Any of these clinical Order ASH FibroSure Blood Test for a noninvasive blood test that evaluates liver function in those suspected of alcoholic liver disease. FibroTest has been evaluated in relation to liver biopsy (the current reference standard in liver disease Noninvasive Fibrosis Testing for Liver Disease John Scott, MD, MSc, FIDSA University of Washington Oct 23, 2018 · Do all patients with liver disease need to have fibrosis testing? Fibrosis testing is relevant for the clinical care of patients with chronic liver disease, including hepatitis B, hepatitis C (HCV), non-alcoholic fatty liver disease (NAFLD), co-infections, primary biliary cirrhosis, primary sclerosing cholangitis, and other chronic metabolic diseases of the liver. ||Separate serum and citrated plasma from cells ASAP or within 2 hours of collection. FibroTest combines five serum biochemical markers (α2-macroglobulin, haptoglobin, γ-glutamyltransferase, total bilirubin, apolipoprotein A1) with patient age and gender [48]. We aimed to systematically review studies describing the diagnostic accuracy of FT for predicting CHB-related fibrosis. FibroTest: The FibroTest uses a proprietary algorithm that includes the individual’s age and sex, along with a composite of five biochemical markers associated with hepatic fibrosis: alpha-2-macroglobulin, haptoglobin, gamma-glutamyltransferase (GGT FibroSURE is a combination of five biochemical assays: alpha2-macroglobulin, haptoglobulin, apolipoprotein A1, gamma glutamyl transpeptidase (GGT) and total bilirubin. NASH FibroSure® Plus is a noninvasive, blood-based diagnostic that provides a comprehensive assessment of metabolic dysfunction-associated steatohepatitis (MASH). It is not recommended for patient with other liver diseases. ||Separate from cells ASAP or within 2 hours of collection. Only intended for use in patients with non-alcoholic liver disease (NAFLD); results may be inaccurate in patients with other etiologies of liver disease. 1 Oct 28, 2025 · The FibroSure® test is an algorithm-based test that provides scores for fibrosis, steatosis and NASH based on the results obtained for several blood markers. The NASH Fibrosure Plus is a more streamlined testing process that looks into the status of your liver. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute hepatitis, acute inflammation of the liver,autoimmune hepatitis, extrahepatic cholestasis, transplant patients, and/or renal insufficiency patients. Features and benefits Non-invasive diagnostic test that evaluates the level of fibrosis in Alcohol is the leading cause of cirrhosis and liver-related mortality, but we lack serum markers to detect compensated disease. Aug 12, 2025 · When to Order FIB-4 vs. 0-1. Features and Benefits Noninvasive diagnostic test that evaluates the level of fibrosis in the liver from blood Learn about non-invasive liver testing (blood & imaging), Fibroscan, FIB-4 & more from Liver Education Advocates. Any of these clinical Oct 27, 2025 · Clinlab Navigator reviews Fibrosure which is a blood test for the detection of liver fibrosis and inflammation. General Approach to Evaluating Liver Fibrosis Fibrosis is a precursor to cirrhosis, and establishing the severity of liver fibrosis helps predict liver-related morbidity and mortality, as well as to inform the need for hepatocellular carcinoma (HCC) screening in persons with chronic HCV. No doctor or insurance needed. However, biopsies are invasive, expensive and can be accompanied by a number of We would like to show you a description here but the site won’t allow us. 2 mL) Lavender (EDTA) or Pink (K2EDTA) for platelet count AND Serum Separator Tube (SST). We aimed to systematically review studies describing the diagnostic accuracy of FT for Oct 5, 2016 · Methods We developed a decision analytic model of noninvasive testing strategies in a hypothetical patient population with genotype 1 HCV infection, with no contraindications to liver biopsy. We used a hierarchical summary receiver operating curves model and the May 11, 2025 · FibroSure, a proprietary test, offers a non-invasive alternative to liver biopsy for individuals affected by chronic liver diseases, including Hepatitis C. 0, S0-S3), and nonalcoholic steatohepatitis (NASH Dec 1, 2025 · Overview of noninvasive methods for assessing hepatic fibrosis, including serologic tests and imaging examinations. Methods 170 patients with suspected NAFLD were Gastroenterology & Hepatology January 2016, Volume 12, Issue 1 Catherine Lucero, MD, and Robert S. This new test is called a Fibrosure or Fibrotest. NASH FibroSure® Plus is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). 0, S0-S3), and alcoholic Apr 10, 2017 · Liver fibrosis tests are necessary for those with chronic liver disease. Apr 10, 2017 · Liver fibrosis tests are necessary for those with chronic liver disease. Discover the stages of NASH, liver fibrosis, and the NASH Fibrosure test. Any of Alphabetical Test listing NASH FibroSure Plus-994 Test info Specimen Performance Clinical and Interpretive info Billing Tracking Test name: Hi Stacy; Fibrosure is a non-invasive technique for determining liver damage. We would like to show you a description here but the site won’t allow us. This noninvasive blood analysis is from the creators of the FibroScan instrument. The gold standard for assessing liver fibrosis is a biopsy. Analyzing 10 biomarkers, NASH FibroSure® Plus uniquely scores three key features of MASH, giving you detailed insights to tailor treatment plans, monitor disease progression and make timely OBJECTIVES: Extent of liver fibrosis is one of the most important factors in determining prognosis and the need for active treatment in chronic hepatitis B (CHB). This test is This test is intended for noninvasive assessment of liver status in patients with alcoholic liver disease. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine We would like to show you a description here but the site won’t allow us. The testing strategies included a testing algorithm using the Fibrosure test, a noninvasive measure of fibrosis, followed by liver biopsy for patients with indeterminate results, Fibrospect II, and The FibroTest (BioPredictive, Paris, France) and FibroSURE (Laboratory Corporation of America, Burlington, NC) are identical proprietary tests marketed under different names in Europe and the United States. Transfer 3 mL serum to an ARUP Oct 5, 2021 · Dear Forum Members, I would welcome thoughts from experienced forum members/participants (I'll be following up with a liver specialist as well). It is not considered accurate for assessing mid stage fibrosis, and yields no information regarding inflammation. In the past, the standard test to determine the physical state of the liver tissue was a liver biopsy. The hepatitis c fibrosure test utilizes a panel of serum biomarkers, attributes of which correlate with the degree of liver fibrosis and inflammation. Oct 12, 2024 · To deal with health problems from hepatitis C, your doctor can measure the amount of fibrosis in your liver. Test Information Oct 27, 2025 · Clinlab Navigator reviews Fibrosure which is a blood test for the detection of liver fibrosis and inflammation. The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD. 99 However, a recent meta-analysis determined that the FibroTest returned the best value for patients with cirrhosis (AUC = 0. Oct 29, 2025 · The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. If reflex FibroTest The FibroTest is a biomarker test that uses the results of 6 blood serum tests (alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, GGT, total bilirubin, and ALT) to generate a score that is correlated with the degree of liver damage. Overall, studies of the various panels suggest they have a good ability to differentiate patients Limitations: NASH FibroSure is recommended for patients with suspected nonalcoholic fatty liver disease. 0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0. Non-invasive means nothing is put inside your body. , Tarrytown, NY), FibroTest (BioPredictive, Paris, France), FibroMAX (BioPredictive, Paris, France) and transient elastography (FibroScan; produced by EchoSens, Paris Abstract Importance The long-term implications of hepatotoxic effects in patients with psoriasis remains uncharacterized, and a method is needed for the noninvasive monitoring of the development and progression of hepatic fibrosis in patients with psoriasis receiving long-term methotrexate therapy. HCV FibroSure has been validated against liver biopsy in multiple studies,1-3 and has demonstrated diagnostic value comparable to liver biopsy in assessing fibrosis. The limitations of biopsy have led to the development of noninvasive tests, w. The test is marketed by LabCorp, but it is not approved by FDA and it is not recommended by evidence-based guidelines. Discuss safe options with your doctor explore smarter liver care today! About liver elastography and FibroScan Liver elastography is a non-invasive test your healthcare provider can use to learn about your liver’s health. Quantitative results of 10 biochemicals in combination with age and gender are analyzed using a computational algorithm to provide a quantitative surrogate marker (0. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra- hepatic cholestasis. FibroTest has the same prognostic value as a liver biopsy. 0, S0-S3) and nonalcoholic Mar 16, 2024 · FibroTest and ActiTest The HCV FibroTest and ActiTest are used for the assessment of liver fibrosis and inflammation, respectively. Both a FibroTest and a Hep Score are done by drawing your blood. Order the test now. Individual results from the 10 component tests are also provided with institution-specific reference intervals. This measurement is called a fibrosis score. It has the same prognostic value as a liver biopsy and can be used for various liver diseases. However, if any of these markers are unusually high or low, the FibroSure® algorithm may not be able to calculate one or more of the scores accurately. It is necessary to further improve the test or combine it with other noninvasive modalities in order to improve accuracy. Find out how it’s created. FibroSure Tests in Outpatient GI Practice FIB-4 should be used as the first-line non-invasive test for liver fibrosis assessment in all patients with suspected NAFLD, while FibroSure (proprietary test) should be reserved for second-tier testing in patients with indeterminate FIB-4 results. C. NASH FibroSure® Plus is recommended for patients with suspected nonalcoholic fatty liver disease. We > = Grade A3 - Severe activity Limitations: The negative predictive value of a Fibrotest score <0. The Fibrosis-4 (FIB-4) Index for Liver Fibrosis is a non-invasive scoring system based on several laboratory tests that help to estimate the amount of scarring in the liver. 0) Patients with chronic HCV (any genotype) who do not have cirrhosis or have compensated cirrhosis and are treatment naïve are eligible for simplified treatment1 All patients with active HCV should be linked to a healthcare provider who is prepared to provide comprehensive management1 AASLD-IDSA recommend the use of non-invasive tests to detect the level of liver fibrosis and help Technology Description: The FibroSure test (marketed as FibroTest outside the United States) measures blood levels of bilirubin, gamma-glutamyl transferase, alanine aminotransferase (ALT), α2-macroglobulin, apolipoprotein-A1, and haptoglobin, which are combined with patient age and sex. 0, S0-S3), and nonalcoholic Non-alcoholic fatty liver disease (NAFLD) is a burgeoning global health concern. Objective To evaluate if NASH FibroSure, a noninvasive test for nonalcoholic steatohepatitis How to Order Please contact your hospital or reference laboratory to inquire about pricing, test-request forms, and billing for this test. 0, S0-S3), and alcoholic FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. 31 (absence of clinically significant fibrosis) was 85% when compared to liver biopsy in 1,270 HCV infected patients with a 38% prevalence of significant liver fibrosis (F2, 3 or 4). Transfer 2 mL serum to an ARUP Standard Transport Tube. Oct 27, 2025 · Clinlab Navigator reviews Fibrosure which is a blood test for the detection of liver fibrosis and inflammation. Both serum and plasma are required for this test. Buy this test online! FibroTest is of value in exclusion of patients with CHB-related cirrhosis, but has suboptimal accuracy in the detection of significant fibrosis and cirrhosis. 0, S0-S3), and nonalcoholic steatohepatitis (NASH FibroSURE is a combination of five biochemical assays: alpha2-macroglobulin, haptoglobulin, apolipoprotein A1, gamma glutamyl transpeptidase (GGT) and total bilirubin. Brown Jr, MD, MPH Dr Lucero is an assistant professor of medicine in the Center for Liver Disease and Transplantation at Weill Cornell Medical Center in New York, New York. Get know how much does lab test cost. Direct access testing with or without insurance. Regardless of etiology, assessing the stage of liver disease is critical for treatment decisions, prognosis and general medical management. 5mL serum from non gel-barrier tube Minimum Volume: 2mL serum from gel-barrier or non gel-barrier tube (this volume does not include repeat or reflex testing) Rejection: Gross hemolysis; gross lipemia; improper labeling; nonfasting specimen; patient younger than 14 years of age. This new test is also quantitative instead of semi-quantitative, which is more useful for the Jul 19, 2016 · Test ID: FNSUR EXPLANATION: The following new orderable, referred to LabCorp Burlington, will be available July 19, 2016. (Min: 1. Using the results from 6 blood serum tests, the doctor can tell a Mar 10, 2019 · Less than two months ago my ultrasound and blood test results were normal but my FibroTest (aka FibroSure) result showed I have Fibrosis stage 3 (F3). Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of adults in developed countries. It seems to correlate with biopsy fairly well when fibrosis is minimal, and again in the later stages of damage; for instance F3 and F4. This addition is known as ActiTest. ASH FibroSure® (LabCorp). NAFLD Fibrosis Score - The NAFLD fibrosis score is a simple noninvasive approach to identify patients that may have significant liver fibrosis and who therefore might benefit from additional studies such as elastography or liver biopsy. Due to the high prevalence of NAFLD, noninvasive risk stratification is Stevenson et al (2012) evaluated the diagnostic accuracy, cost-effectiveness, and effect on patient outcomes of 4 non-invasive tests for liver fibrosis [the Enhanced Liver Fibrosis (ELF) test (Siemens Healthcare Diagnostic Inc. It is not recommended for patients with other liver diseases. Oct 27, 2025 · FibroSURE is a patented algorithm that uses six or ten serum markers to estimate the stage and grade of liver fibrosis and inflammation in patients with hepatitis C, NASH or other chronic liver diseases. Another Oct 21, 2003 · Only Noninvasive Option That Quantifies the Degree and Rate of Liver Fibrosis in HCV Patients BURLINGTON, N. (Video 6. The results of these assays are factored together, along with patient Noninvasive assessment of liver fibrosis and necroinflammatory activity for patients with HCV HCV FibroSure® is a noninvasive blood test of 6 biochemical markers that provides METAVIR fibrosis staging and necroinflammatory grading. In the subset of NAFLD patients with non-alcoholic steatohepatitis (NASH), the presence of significant fibrosis at index assessment is associated with poor prognosis Jun 14, 2020 · FibroScan and FibroSure A FibroScan test is designed to measuring the liver’s stiffness using elastography, and these tests have been used for several years now. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or, extra-hepatic cholestasis. There are other similar techniques such as Fibrospect, etc. Labcorp test details for FIB-4 FIB-4 index is reported to be a simple, accurate, non-invasive, and readily available laboratory test index that can help in evaluation of patients with HCV and Non-Alcoholic Fatty Liver Disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), for the presence of liver fibrosis indication for liver biopsy and other liver Mar 15, 2024 · Gastroenterology & Hepatology June 2024 - Volume 20, Issue 6 A Clinical Review of Noninvasive Tests for Hepatic Fibrosis FibroTest, known as FibroSure in the US, is a patented biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases. The results can guide treatment plans, lifestyle modifications, and FibroMeter is a blood test used to aid in the evaluation and management of liver fibrosis. Do not send the EDTA whole blood to ARUP. While liver biopsy remains the reference method for managing patients with chronic liver disease, FibroMeter may be used for patients who may be at risk of complications, and to support biopsy results. The most studied panels are the aspartate aminotransferase (AST) to platelet ration (APRI), FibroTest/FibroSure, Hepascore, and FibroSpect. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine Useful For This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Launch of Exclusive Liver Fibrosis Assay HCV FibroSURE (TM) Enhance your MASH management with NASH FibroSure® Plus. The FibroSure® test is an algorithm-based test that provides scores for fibrosis, steatosis and NASH based on the results obtained for several blood markers. 2 Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease Aug 12, 2025 · FIB-4 should be used as the first-line non-invasive test for liver fibrosis assessment in all patients with suspected NAFLD, while FibroSure (proprietary tes This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). NASH FibroSure® Plus provides a noninvasive assessment of liver status in patients with metabolic-associated steatotic liver disease (MASLD), analyzing 10 biochemicals with age and gender to generate quantitative markers for liver fibrosis, hepatic steatosis, and MASH. This test combines NASH FibroSure® Plus with potential reflex to the Enhanced Liver Fibrosis (ELF™) test. The first 3 markers are common in liver function test panels. , Oct 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Laboratory Corporation of America Holdings (NYSE: LH) (LabCorp(R)) and BioPredictive, a French diagnostics firm, today announced an Mar 4, 2025 · NASH FibroSure Plus focuses on patients with suspected NASH, whereas the R Plus variant includes additional parameters for broader liver health evaluation. Disease stage is determined by liver biopsy and the pathologist utilizes a scoring system such as the Metavir or Ishak systems to quantify the amount of fibrosis. Dr Brown is the vice chair of Transitions of Care and the interim chief of the Division of Gastroenterology and Hepatology NASH FibroSure (R) is recommended for patients with suspectednonalcoholic fatty liver disease. An additional component – alanine aminotransferase (ALT) – is infrequently used to test for necroinflammatory lesions. Noninvasive serum test to assess for surrogate markers of liver fibrosis in individuals with chronic viral hepatitis. Oct 11, 2023 · Hep C, FibroSURE Liver Fibrosis LIVFIB Fibrosure, HCV NASH Replacement Test 550960 LabCorp test code (LB). Noninvasive methods to estimate hepatic fibrosis are commonly used in clinical practice as a safer, more This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). This test is intended for noninvasive assessment of liver status in patients with alcoholic liver disease. S. 2 Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). It creates a score, and combined with other liver tests is s great way to diagnosis liver disease. Learn how to diagnose fatty liver disease, its progression, and NASH's impact on liver health. BioPredictive is an independent bio-pharmaceutical company, based in France, which designs and markets diagnostic tests for liver diseases, in particular FibroTest and NASH-FibroTest. This test provides numeric scores that assess hepatic fibrosis (FibroTest), hepatic inflammation (NashTest 2), and steatosis (SteatoTest 2). Mar 18, 2019 · The NASH-FibroTest includes three noninvasive tests that enable clinicians to make a diagnosis and follow-up treatment decisions: NashTest 2, SteatoTest 2, and FibroTest. Hepatitis B Virus (HBV) FibroSure® Test Number 550605 CPT [MAAA: 81599] or 82172; 82247; 82977; 83010; 83883; 84460 Synonyms Actitest FibroSure® FibroTest Share Print Include LOINC® in print Test Details Specimen Requirements LOINC® Order a Hepatitis C Virus Blood Test, FibroSure for a noninvasive blood test to evaluate liver damage from HCV infection. Anticoagulant therapy with warfarin or other anticoagulants that prolong the prothrombin time may affect test results. Physicians may order these tests for patients with abnormal liver function tests, metabolic syndrome, obesity, diabetes, or unexplained fatigue and abdominal discomfort. 48 (F2, 3, 4) was 61% in that same patient cohort. Quantitative results of 10 biochemicals in combination with age, gender, height, and weight are analyzed using a computational algorithm to provide a quantitative surrogate marker (0. During a liver biopsy a fine needle is pushed into the liver and a sample of liver tissue is taken FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. Noninvasive alternatives such as FibroTest/Fibrosure (FT) have been developed in order to overcome the shortcomings of liver biopsy (LB). The liver specialist told to that I will need to We would like to show you a description here but the site won’t allow us. Interpretation of the scores is provided in the report. This test was specifically designed for patients with chronic viral hepatitis (with or without HIV coinfection). Clinical Significance Liver Fibrosis, FibroTest-ActiTest Panel - FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. HCV Apr 2, 2024 · A new test to determine if fibrosis (cirrhosis) is present in the liver is now available and is a breakthrough for patients with liver disease. Knowing the severity of We would like to show you a description here but the site won’t allow us. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 FibroTest, also known as FibroSure in the US, is a blood test that measures six serum markers and calculates a score correlated with the degree of liver fibrosis and inflammation. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin Specimen Requirements Preferred Specimen: 3. We compared the accuracy of the Enhanced Liver Fibrosis test (ELF), the FibroTest, liver stiffness measurements (made by transient elastography and 2-dimensional shear-wave elastography), and 6 indirect marker tests in detection of advanced liver fibrosis (Kleiner Feb 14, 2006 · Background Liver biopsy is considered as the gold standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The positive predictive value of a Fibrotest score >0. The new NASH-FibroTest is based on the latest, more simplified histological definition of MASH from the Clinical Research Network. Buy online! Feb 1, 2026 · ELF Test vs NASH FibroSure Plus for Liver Fibrosis Assessment For assessing liver fibrosis in NAFLD/NASH, the Enhanced Liver Fibrosis (ELF) test is the preferred second-line test after FIB-4 screening, as it has superior guideline support and validated diagnostic performance compared to NASH FibroSure Plus, which lacks guideline endorsement and independent validation studies. Scores based on laboratory values and demographic variables have been developed and validated for assessing fibrosis in patients with hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD), as have several imaging methods that measure shear-wave May 5, 2015 · Chronic liver disease due to a variety of etiologies is a leading cause of morbidity and mortality in the US. 0, S0-S3), and nonalcoholic steatohepatitis (NASH Feb 14, 2006 · In patients with NAFLD, FibroTest, a simple and non-invasive quantitative estimate of liver fibrosis reliably predicts advanced fibrosis. Find out why your physician may order a combination of liver biopsy and/or non-invasive liver fibrosis testing, as well as the pros and cons of these methods. Specimen Type: Serum Supplies: Sarstedt 5 mL Aliquot Tube (Amber) (T915) Collection Container/Tube: Preferred: Serum gel Acceptable: Red top Submission Container/Tube: Amber vial Specimen Volume: 4 mL Specimen Type: Plasma Collection Container/Tube: Grey top (potassium oxalate/sodium fluoride) Submission Container/Tube: Plastic vial Specimen A variety of serologic markers have been evaluated to predict the degree of fibrosis. 92) and moderate values Mar 17, 2004 · LabCorp (R) Announces U. METHODS: MEDLINE and EMBASE searches and hand searching methods were performed to identify studies that assessed the diagnostic accuracy of FibroTest in HB patients using LB as a reference standard. This noninvasive, blood-based diagnostic provides a comprehensive assessment of metabolic dysfunction-associated steatohepatitis (MASH). Last year I had a FibroSure test done in November Liver Fibrosis, FibroTest-ActiTest Panel – FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. They combine assays of multiple markers to improve predictive ability. lsq qoupjnn fsen zwrfm nmvyvx bdmfv jmsfp yzihovm ihcgc gjkdp